title: Treating severe malaria in pregnancy: a review of the evidence.
abstract: Severe malaria in pregnancy is a large contributor to maternal morbidity and mortality. Intravenous quinine has traditionally been the treatment drug of choice for severe malaria in pregnancy. However, recent randomized clinical trials (RCTs) indicate that intravenous artesunate is more efficacious for treating severe malaria, resulting in changes to the World Health Organization (WHO) treatment guidelines. Artemisinins, including artesunate, are embryo-lethal in animal studies and there is limited experience with their use in the first trimester. This review summarizes the current literature supporting 2010 WHO treatment guidelines for severe malaria in pregnancy and the efficacy, pharmacokinetics, and adverse event data for currently used antimalarials available for severe malaria in pregnancy. We identified ten studies on the treatment of severe malaria in pregnancy that reported clinical outcomes. In two studies comparing intravenous quinine with intravenous artesunate, intravenous artesunate was more efficacious and safe for use in pregnant women. No studies detected an increased risk of miscarriage, stillbirth, or congenital anomalies associated with first trimester exposure to artesunate. Although the WHO recommends using either quinine or artesunate for the treatment of severe malaria in first trimester pregnancies, our findings suggest that artesunate should be the preferred treatment option for severe malaria in all trimesters.
authors.affiliation: Department of Epidemiology, University of Washington, Seattle, WA, USA, Kovacs2@uw.edu.
authors.forename: Stephanie D
authors.initials: SD
authors.lastname: Kovacs
authors.forename: Marcus J
authors.initials: MJ
authors.lastname: Rijken
authors.forename: Andy
authors.initials: A
authors.lastname: Stergachis
mesh_terms: D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D047108:Embryonic Development / Q000187:drug effects*; D005260:Female; D006801:Humans; D008288:Malaria / Q000150:complications / Q000188:drug therapy* / Q000469:parasitology; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy*; D014944:World Health Organization
chemical_list: D000962:Antimalarials